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Objectives . This study was designed to investigate In patients
the effect of a new transpulmonary echo contrast agent, made
from 5% human serum albumin (Albunex), on systemic and
pulmonary hemodynamics and the influence of the contrast doses
on left ventricular opacification .
Background. New Intravenous trauspuhnonary echo contrast
agents are promising, allowing contrast stress echocardiography
and myocardial contrast echocardiography . Nevertheless, some
shortcomings still remain . Thus, the pulmonary hypertension
observed in pigs after Albunex injection should be investigated in
humans, and the optimal dose of contrast agent remains to be
determined because previous experiments indicated that the left
ventricular opacification and attenuation are dose dependent .
Methods . Albunex in doses of 0 .08 and 0.22 mI/kg was succes-
sively Injected intravenously in 20 catheterized patients; in I I of
them, anti-inflammatory drugs were withdrawn to avoid the
blocking of an eventual thromboxane-mediated pulmonary- artery
hypertension . Systemic blood pressure and pulmonary artery,
capillary wedge and right atrial pressures were continuously
To date, myocardial perfusion assessment has been achieved
mainly after intraaortic or intracoronary injections of echo
contrast agents . The determination of myocardial perfusion
defects (1-3), area at risk (4,5), cardioplegic efficacy (6,7),
coronary blood flow (8,9) . coronary flow reserve (10,11) .
perfusion by collateral flow (12,13) and efficacy of percuta-
neous transluminal coronary angioplasty or thrombolysis
procedures (14,15) have therefore been limited to invasive
settings in either the cardiac catheterization laboratory or
the operating room . Recently, intravenous and right atrial
injections of sonicated microbubbles made from 5% human
albumin have been shown to result in a dose-dependent,
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monitored. Cardiac output, left ventricular fractional shortening
and blood gases were determined 5 min before and 5 and 10 min
after each injection . The left ventricular apacification was quali-
tatively assessed by three independent observers using a grading
settle from 0 to 3, with 0 indicating an absence of contrast effect
and 3 indicating full opacification .
Results. No clinical, hemodynalnic or respiratory adverse
reactions were observed in any patient. Irrespective of doses, a left
ventricular opacificallon grade 72 was observed in 74% of the 35
injections that could be evaluated . This percentage Increased to
94% when the higher dose group was considered alone .
Conclusions. This first report of the effect of Albunex injected
intravenously on pulmonary artery pressures in hsomans demon-
strates that this contrast agent appears to be safe. The significant
left ventricular opacification obtained in a majority of patients
without an important increase in attenuation supports the use of
the higher dose of the contrast agent .
(,l Am Coll Cardiol 1993;22:1193-8)
reproducible myocardial opacification (16,17) . These find-
ings, together with the development of contrast stress echo-
cardiography (18,19), will lead to a br 'ader utilization of
these contrast agents . Previous studies have demonstrated
that a new transpulmonary echo contrast agent, Albunex,
does not affect the left heart function in humans (20,21), but
very few data are available regarding its effect on pulmonary
artery pressures. Because nonsymptomatic effects could be
missed ii subjects not fitted with monitoring instruments
and, more spccifcally, because the severe pulmonary hyper-
tension observed in some animals after exposure to Albunex
(22.23) could theoretically occur in humans (24-26), we
investigated invasively the hemodynamic and respiratory
effects of this sonicated human albumin in patients .
The second goal of the study was to investigate the effect
of two different Albunex doses on the degree of left ventric-
ular opacification . Indeed, the left ventricular opacification
and the occurrence of attenuation are dependent on the
concentration of the contrast agent used, and thus an optimal
dose remains to be determined (27,28) .
0735 .1097/930
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Table 1
. Time Course of Hemodynamic Variables Before, During and After Albunex Injections in
20 Patients
Methods
Study patients. The study was carried out on 20 patients
with ischemic heart disease (17 men and 3 women, mean age
54 ± 9 years, weight 77 ± 10 kg and height 1 .71 ± 0 .1 ml
referred for cardiac catheterization procedures for either
diagnostic coronary angiography or coronary angioplasty
(left anterior descending coronary artery [n = 91, left cir-
cumflex coronary artery [n = 61 or right coronary artery [n =
4j). The systolic and diastolic artm al blood and pulmonary
artery pressures were 142 ± 25169 ± 14 mm Hg and 28 ±
8113 ± 5 mm Hg, respectively . The mean left ventri:ular
telediastolic pressure was 11 ± 5 mm Hg . Mean systemic,
P*WWry artery, pulmonary capillary wedge and right aural
pressures are presented in Table 1 . All patients had sinus
rhythm. The exclusion criteria were 1) women of childbearing
polentlal, 2) history of blood product allergy, 3) adult respira-
tory distress syndrome, and 4) heart failure or angina grater
than class 3. No selection was based on echocardiographic
criteria
. In 11 of the 20 patients, anti-inflammatory drugs were
withdrawn to avoid the blocking of an eventual thromboxane-
mediated pulmonary hypertension. The protocol was approved
by the Institutional Review Board for human studies, and all
patients signed an informed consent form before participating
in the study.
Study dWp. The study was designed as an open label
study in which the patient served as his or her own control.
It consisted of three periods-1) prestudy, 2) test, and 3) 24-h
follow.up. During the prestudy period, clinical and labora-
tory examinations were performed ; then the patients under-
went diagnostic coronary angiography (I patient) or control
coronary angiography 24 h after coronary angioplasty (19
patients)
. The test period consisted of two successive intra-
venous Albunex injections after 30 min at rest in supine
For baseline and IS min after Injection . the data arc expressed as mean value ± SD. The other data ere expressed
as mean change ± SD from baseline 0 for the first injection and from 15 min after the first injection for the second
injection . PAP pulmonary artery pressure
; PCWP - pulmonary capillary wedge pressure ; RAP - right atrial
pressure ; SBP systemic blood pressure .
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position. Injections were performed at] 5 min apart to enable
vital signs to be measured after each injection and to ensure
clearance of the remaining contrast medium from the previ-
ous injection. Patients were monitored for clinical and non-
symptomatic hemodynamic and respiratory adverse events
throughout the procedure . Clinical status and systemic blood
pressure were then checked every hour for 6 h and every 4 h
for the remaining of the 24-h follow-up period . An electro-
cardiogram (ECG) was then obtained .
Patient Instrumentation . Nineteen of the 20 patients were
fitted with monitoring instruments 24 h before Albunex
exposure, that is, during coronary angioplasty ; one patient,
underwent instrumentation on the day of the Albunex study .
Cardiac output, pulmonary artery, capillary wedge and right
atrial pressures were determined with a 7F Swan-Ganz
catheter placed through a femoral vein. A 7F introducer
sheath was inserted in a femoral artery for systemic blood
pressure monitoring and arterial blood sampling . An 18-
gauge catheter was placed in a brachial vein for injection of
Albunex .
Measurement and analysis. Biochemical variables . Arte-
rial blood samples were withdrawn 5 run before and 5 and
10 min after each Albunex injection to determine the arterial
blood gases, pH, bicarbonates and arterial oxygen saturation
(Blood Gas System 288, Ciba-Corning) .
Hemedynamic measurements . All pressures were moni-
tored continuously using a fluid-filled recording system con-
nected to a multichannel recorder (Honeywell VR •12). Rep-
resentative tracings were recorded on a strip chart recorder,
and values were reported at baseline (-5 and 0 min) and at
1, 3, 5, 10 and 15 min after the first Albunex injection and at
1, 3, 5 and 10 min after the second injection . Cardiac output
was determined by thermodilution (Cardiac Output Com-
Mean Pressures (mm Hg)
SBP PAP PCWP RAP
Baseline
-S min 91 t 15 17 1 5 9.314.3 6
.9 ±± 4
.6
0 min 95 ± 16 18 :t:
10.4±4.1 6.9±4 .9
After first injection
I min -1.1 ± 7 .7 -1.713 .2 -0.3x3.5 0.011 .6
3min -1.4±7.5 -1 .213 .1 -0.414.8 -0 .1
1
1.7
S min -2.3 t 6.7 -1 .5 1 2 .5 0.1 ± 2.9 0 .21 1 .9
10 min -1.3 t 6.6 -1.012 .8 --n.2 1 2.3 -0 .1 * 2 .1
IS min 95 t 15 17±7 10.2±4.5 6.5±5.2
After second Injection
I min -0.9 t 6.9 -1 .3 t 3 .9 -0.2 ± 3 .0 0
.4 ± 3
.0
3 min -0.2 ± 4.6 -0.5 t 3 .2 0.1 t 2 .5 G .7 ± 3 .5
5 min -0.1 15.7 -0.8 t 2 .1 0.0 ± 2.3 0 .1 ± 2 .7
10 min 1 .5 t 5.5 0.9 t 3 .0 0.01 2.5 -0 .1 ± 2.7
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Table 2 . Time Course of Cardiac Output
(CO), Fractional Shortening (FS) and Heart Rate (HR)
is
puter COM-1, American Edwards Laboratories) and was
calculated as the mean of three to five measurements . Ten
milliliters of cold (0 to 3"C) saline solution was injected by
hand. Carbon monoxide and fractional shortening were
determined 5 min before and at 5 and 10 min after each
injection . Heart rate and capillary oximetry were determined
continuously by Supermon 7210 (Kontron Instruments). An
ECG lead 11 (Honeywell VR-12) was recorded continuously
to detect any rhythmic or isehemic changes .
Eehocardiographic examination and contrast evaluation .
Two-dimensional echocardiography was performed with a
phased array system (Ultramark 9 or 7, Advanced Technol-
ogy Laboratories) with a 2 .25-MHz transducer. The patients
were examined in either the supine or the lateral decubitus
position . Fractional shortening was determined according to
American College of Cardiology standards by using the best
echocardiographic window, either the left parasternal or the
subcostal. Contrast images were obtained using the apical
four-chamber view . Gain was initially optimized during each
experiment and kept unchanged throughout. The images
were recorded from before the injection until clearance of
the contrast agent on VHS videotape (Panasonic VHS 625) .
The left ventricular opacification grading was qualitatively
assessed by three independent observers using a grading
scale from 0 to 3, with 0-1 indicating an absent or faint
contrast effect and 2-3 indicating intermediate or full opaci-
fication . Attenuation was graded as none, partial or :om-
plete .
Contrast agent. Sonicated microspheres made from 5%
human serum albumin (Albunex), at a concentration of 2 x
108 microspheres/ml with a diameter of 4 to 10 µm were
DENY ET AL.
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Data are expressed as mean changes from baseline ± SD . Each variable
was determined S min before and 5 and
10 min after each injection .
used. Albunex in doses of 0.08 and 0.22 ml/kg body weight
was injected manually at a rate of I ml/s followed by a flush
of saline solution for 1(i i .
Statistical methods . Multivariate analysis of variance for
repeated valves was used to detect changes in hemodynamic
and respiratory parameters . The McNemar test was used to
assess the contrast agent dose
effect
on the left ventricular
opacification . A significance level of 5% was applied in the
multivariate and McNemar tests . Data are expressed as
mean value ± I SD.
Results
Safety. No immediate or delayed clinical or ECG adverse
reaction related to Albunex occurred in any patient .
Table I demonstrates the time course for the 20 patients
of mean systemic blood pressure and mean pulmonary
artery, capillary wedge and right atria] pressures shown as
mean changes from the baseline values . The time course of
cardiac output, fractional shortening, heart rate and arterial
blood variable are expressed similarly in Tables 2 and 3 . No
statistically significant changes were observed for the hemo-
dynamic and respiratory variables studied at any time of
measurement except for 1) decrease in mean pulmonary
artery pressure, 2) increase in fractional shortening at 5 min
after the first injection, and 3) increase in oxygen tension
10 min after the second injection . However, no variation was
clinically significant .
Results in the subgroup without anti-inflammatory treat-
ment were similar, for most of the variables studied, to those
observed for the total group of 20 patients . The time course
Table 3 .
Time Course of Arterial Blood Gas Variables Before and After Albunex Injections in
Data are expressed as mean changes from baseline ± SD . Hco
s = bicarbonates : Pao2
= arterial partial pressure
of oxygen; Paco2
= arterial partial pressure of carbon dioxide
: Sao2 = arterial blood oxygen saturation
. Each
variable was determined 5 min before and 5 and 10 min after each injection
.
20 Patients
Baseline
After First Injection
After Second Injection
-5 min 5 min IO min
5 min
10 min
CO (itershuin)
6
.8 ± 1 .2 -0.2 t 0 .3 -0.3±0.4
-0.3±0.5 -0.3 ± 0.5
FS 1%)
33.815.5 2.9±2.9 0.9±4.0 1 .3 ± 3 .2
1 .2 ± 4.9
HR (beats/min) 71 .0 ± 7.6 -2.0 ± 3
.8
-2.0±3
.8 -3.0 ± 3.8
-2.6 ± 4 .7
20 Patients
Baseline
-5 min
After First Injection
After Second Injection
5 min
10 min 5 min
10 min
pH (literstmin) 7 .4 ± 0 .0 0.0 ± 0.0 0
.0 ± 0.0 0.0 ± 0
.0 0.0 ± 0.0
Pao2 (kPa) 11 .1 ± 1 .5 0.0 ± 1 .8
0.6±1 .8 0.6±1
.7 1.0±1.3
Paco2 (kPa) 4 .9 ± 0 .4 -0.1 ± 0
.3 0 .0 ± 0 .4
0 .1 ± 0,2 0.0 ± 0.3
Hco 3 (mmol) 22 .8 ± 2 .8
-0.4 ± 1 .9
-0.2 ± 1 .5 0 .4 ± 1 .0 0
.1 ± 1 .3
Sao2 (%) 95.8 ± 1 .7 0.3 ± 1
.1 0 .4 ± 1 .2 0 .4 ± 1 .1
0.6 ± 0.8
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Flgnre 1 . Time course of systolic (circles), mean (squares) and
diastolic (triaa pulmonary artery pressure (PAP) in I I patients
without
anti-inflammatory treatment . inj
z
Albunex injection, Re-
sults are expressed as mean value ± 1 SE .
of pulmonary pressures for the l1 patients is presented in
Figure 1 . It demonstrates a statistically significant time effect
indicating a slight decrease in mean pulmonary artery pres-
sure in the first minutes after Albunex injection.
EMcaey. For technical reasons, the low dose injection
was not evaluated in one patient, and no injections were
evaluated in two other patients because of very poor echoge-
nicity . The lower dose of Albunex (0 .08 mllkg) led to full
right ventricular opacification in all injections that could be
evaluated (100%) . This opacificutson was usually associated
(80% of the cases) with complete attenuation of the right
heart image, presumably because of the effects of acoustic
shadowing. The left ventricular opacification was graded as
0-1 in 8 (47%) and as 2-3 in 9 (53%) of these 17 intravenous
injections that could be assessed . No attenuation occurred in
the left ventricle . The use of the higher dose of Albunex
(0,22 mllkg) was characterized by a striking enhancement in
left ventricular opaciftcation . Thus, the grading was judged
as 0-1 in only one case (6%) and 2-3 in t7 (94%) of the 18
considered injections. A partial left ventricular attenuation
was observed in two cases, whereas right ventricular opaci.
ficatimt and attenuation were similar to those observed when
low Albunex dose was used .
Ulscussion
This clinical study evaluates simultaneously for the first
time the effect of intravenously administered Albunex on the
pulmonary artery and systemic pressures in patients with
ischemic heart disease, Indeed, this group will presumably
benefit the most from contrast echocardiographic studies
through myocardial perfusion assessment and stress contrast
echocardiographic examination. In addition, the relative
action of Albunex doses on left ventricular opacification was
investigated.
Sd*. In humans, as in most animal species (29,30),
Albunex is considered to be safe, and only a small number of
adverse reactions-brief and spontaneously resolved-have
JACC Vol. 22, No . 4
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been observed (20,21) . Nevertheless, few studies have been
performed on subjects fitted with monitoring instruments
and, more specifically, few data are available concerning the
effect of Albunex on the pulmonary artery pressures . In
dogs, intravenous injection of individually prepared soni-
cated albumin microspheres had a deleterious effect on
pulmonary hemodynamics and oxygen saturation, but the
absence of similar adverse effects using commercially pre-
pared sonicated albumin (Albunex) suggests that the prepa-
ration method was responsible for the adverse outcome (28) .
However, the effect of Albunex on pulmonary artery pres-
sures in humans remains to be investigated because Os-
tensen et al . (23) observed a thromboxane-mediated pulmo-
nary hypertension in pigs after exposure to intravenous
Atbunex. Indeed, this reaction is thought to be secondary to
species-related pulmonary intravascular macrophages, cells
responsible for the nearly complete removal by the lung of
intravenous injected particles (31,32). The phagocytosis pro-
cess results in release of the vasoconstrictive agent throm-
boxane, thereby causing severe pulmonary hypertension
(33) . In humans such pulmonary intravascular macrophages
have been observed in patients after injury to the lungs and
also in normal subjects, raising the question whether Al-
bunex could also cause pulmonary hypertension in patients
(24-26) . If it did, possible nonsymptomatic effects on pul-
monary artery pressure could be observed only by invasive
pressure measurements .
Our results in the 20-patient group demonstrate that
Albunex, administered intravenously, does not adversely
affect the clinical and respiratory status of patients, and does
not alter left heart function (20,21). Moreover, no deleterious
effect was observed on pulmonary hemodynamics or the
arterial partial pressure of oxygen .
Nevertheless, it has been demonstrated in pigs that the
adverse reactions can be blocked by anti-inflammatory drugs
through antagonism of the pathway of arachidonic acid
metabolites (23). Therefore, in a subgroup of 11 patients, we
took care to withdraw such drugs, aspirin and corticoster-
oids, which are usually given before coronary angiography .
In view of the eventual thromboxane release, the findings
were contrary to expectations, in that a significant decrease
was found in mean pulmonary artery pressure during the first
minutes after Albunex injections . Thus, no pulmonary hy-
pertension was observed in our patients. Overall, although
statistically significant, the variations observed in some of
the variables studied were very slight and were probably not
of clinical importance .
Quality of contrast effect. Previous studies have demon-
strated the ability of microbubbles to cross the lung capillar-
ies after intravenous injection (16-19). The degree of left
ventricular opacification is thought to depend on the echoge-
nicity of the patient and the acoustic properties of the
contrast agent . No patient was selected on the basis of
echogenicity criteria, explaining the absence of left ventric-
ular opacification grading in two cases because of very poor
echogenicity (34) . Conversely, site of injection, volume,
JACC Vol . 22, No . 4
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concentration and injection rate of the contrast agent are
critical variables (20,28) . In this study, each patient served
as his or her own control, and site of injection, concentration
and injection rate of the contrast agent were kept constant .
Thus, the left ventricular opacification and its limitation by
attenuation were essentially dependent on the volume of
Albunex injected. Doses of 0 .08 and 0.22 ml/kg were used
because lower doses have been shown (20) to be inadequate
for left ventricular opacification in most patients . As previ-
ously reported (20,28), our data demonstrate an Albunex
dose dependence of the left ventricular opacification . In-
deed, the degree of left ventricular opacification was signif-
icantly more often > 1, using the higher dose of Albunex
(949io vs. 53% with 0 .22 vs. 0.08
ml/kg).
Irrespective of
doses, a left ventricular opacification grade ~-_2 was observed
in 74% of the 35 injections that could be evaluated . Because
attenuation (two patients) was rare and only partial, these
results support the use of the higher rather than the lower
dose of Albunex when performing contrast echocardio-
graphic examination in patients.
Conclusions. Our data indicate that intravenously admin.
istered Albunex is safe in humans . Neither adverse clinical
reactions nor deleterious (even nonsymptomatic) effects on
systemic and pulmonary hemodynamics were observed even
after the withdrawal of anti-inflammatory drugs . The signif-
icant left ventricular opacification obtained in almost all
cases when the higher dose of contrast agent was used
supports the use of a similar dose in a nonselected patient
group. These results will allow a broader use of this new
transpulmonary echo contrast agent, particularly in the
promising fields of contrast stress echocardiography and
myocardial perfusion assessment .
We acknowledge Marit Lambrcchts, PhD for efficient help in designing the
study. We are indebted to the catheterization laboratory and to the intensive
care unit teams for their support and to Hanne Narbuvold, PhD for statistical
analysis of the data .
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